Initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression, and anxiety.
electroCore was founded in 2005 and has more than 30 employees and full-time consultants, with offices in the US (global headquarters), Germany (German and European head office), UK, Italy, Australia, and Canada.
electroCore’s headquarters in Basking Ridge, New Jersey, USA
FundingelectroCore is a privately held company which has raised over $70 million through multiple rounds of funding. In March 2013 the company announced completion of a $40 million round led by Merck Global Health Investments and two private equity groups (Easton Capital and the founder’s group, Core Ventures).
Intellectual Property (IP)electroCore has secured its IP with over 60 patents and patent applications in the US and PCT. Significant scope has already been allowed by the US patent office, including coverage for the proprietary signal, methods of treatment, the non-invasive delivery means, and the mechanisms of central action. Continued developments in the device offer a near evergreen potential for maintaining patent protection. The company has no obligations to third parties for its IP, and is not blocked from any of its key markets by the IP of other parties.
RegulatorygammaCore is a class IIa medical device, granted CE marks for use in the following indications; primary headache, bronchoconstriction, epilepsy, gastric motility disorders, and depression and anxiety. gammaCore has recently been issued guidance under the NICE interventional procedures process that electroCore’s non-invasive vagus nerve stimulation treatment (gammaCore) for the prevention and acute treatment of migraine and cluster headache is safe and can now be used in the NHS (https://www.nice.org.uk/guidance/ipg552).
On April 14th 2017, the CDRH division of the US FDA released gammaCore for the acute treatment of pain associated with episodic cluster headache in adult patients. gammaCore also has regulatory approval for the acute and/or prophylactic treatment of cluster headache, migraine and medication overuse headache in South Africa, India, New Zealand, Australia, Colombia, Brazil and Malaysia, and in Canada for cluster headache and treatment of migraine.